Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the unanswered questions that remain with atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma (mUC).

Dr. Nanus on Next Steps With Atezolizumab in Patients With mUC

Final Thoughts on Immunotherapy

The Next Wave in Checkpoint Inhibition

Oncolytic Viruses: Melanoma and Bladder Cancer

Managing Immunotherapy-Related Toxicity

Optimal Duration of Immunotherapy

Immunotherapy in Novel Settings

The Emergence of PD-L1 Inhibitors

Combined Targeting Against VEGF and PD-1 in Bladder Cancer

The FDA Approval of Atezolizumab in Bladder Cancer

PD-1 Inhibitor Use in Melanoma

PD-1 Inhibitor Use in Kidney and Bladder Cancers

PD-1 Inhibitor Use in Advanced Lung Cancer

Adoptive Cell Therapy and Antibodies

Immunotherapy Modalities: Checkpoint Inhibitors and Vaccines

The Immune System and Cancer Pathogenesis

Dr. Keith Kerr on Selecting Patients for Immunotherapy in Lung Cancer

Suzanne L. Topalian, MD, discusses progress in PD-1/PD-L1 immunotherapies and the prospects for developing biomarkers to better identify patients who would benefit from the new agents.

Immunotherapy Perspective From a PD-1 Pioneer

The first prospective study to investigate the use of immunotherapy in patients with squamous cell carcinoma of the anal canal demonstrated promising results following treatment with nivolumab.

Nivolumab Spurs Encouraging Responses in Metastatic Anal Cancer

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.

Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCC

Immuno-Oncology

Immuno-Oncology | Specialty